First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )

Summary

This study tests an investigational cancer vaccine called ITI-5000 in people who have completed standard treatment for early-stage triple-negative breast cancer (TNBC). ITI-5000 is a self-amplifying RNA (saRNA) vaccine that instructs the immune system to recognize and attack cancer cells expressing two proteins found on TNBC cells-HERV-K and CT83-fused with a molecule called LAMP-1 that helps the immune system respond more strongly. The vaccine is delivered inside lipid nanoparticles (LNPs), similar to other approved mRNA vaccines. The study has two parts: * Part A: Participants receive ITI-5000 alone at one of two dose levels (1 µg or 10 µg), given as an injection into the upper arm muscle every 28 days for 3 doses total. The goal is to find the safest dose. * Part B: Participants receive ITI-5000 at the best dose identified in Part A, combined with an approved immunotherapy drug called pembrolizumab (Keytruda®), every 21 days for 3 doses total.

Eligibility

Inclusion Criteria:

* Age: Adults aged 18 years or over.
* Consent: Provided a signed and dated informed consent form (ICF).
* Diagnosis: Histologically confirmed stage 2-3 triple-negative breast cancer (TNBC), defined as HER2-negative, ER-negative, and PgR-negative by immunohistochemistry. BRCA mutations are allowed.
* Prior Treatment: Completed all planned standard therapy (surgery, chemotherapy, radiation, and/or pembrolizumab as applicable) and be within 36 months of definitive surgery.
* Performance Status: ECOG performance status of 0 or 1.
* Organ Function: Adequate organ function at baseline (hematology, biochemistry, etc.).
* Cardiac Function: No significant ischemic heart disease or myocardial infarction within 3 months before vaccination #1; QTc ≤470 msec for females or ≤450 msec for males.
* Pregnancy: Women of childbearing potential must have a negative serum pregnancy test within 3 days before vaccination #1 and agree to use highly effective contraception during the study and for 123 (Part A) or 137 (Part B) days after last study drug.
* Compliance: Able to attend required study visits and follow-up.
* Understanding: Able to understand and provide signed informed consent per IRB/IEC guidelines.
* Vaccinations: Agrees not to receive routine vaccinations until at least 30 days after the last study vaccine.
* Alternative Therapies: Agrees not to use alternative therapies from the time of informed consent through 30 days following vaccination #3.

Exclusion Criteria:

* Part B only: Discontinued prior treatment with an immune checkpoint inhibitor (ICI) due to immune-related adverse events (irAEs).
* Recent Surgery/Therapy: Major surgery within 4 weeks before vaccination #1 or received cancer-directed therapy or investigational drug/device within 4 weeks or 5 half-lives before vaccination #1.
* Part B only: Received other PD-1/PD-L1 inhibitors (besides pembrolizumab) without proper washout.
* Toxicities: Unresolved toxicities from prior immunotherapy or chemotherapy (must be ≤ Grade 1 or baseline, or deemed irreversible and not worsened by immunotherapy).
* Medical Illness: Significant medical illness, underlying health condition, or abnormal laboratory finding increasing risk.
* Autoimmune Disease: Active autoimmune disease requiring immunosuppressive treatment within the last year.
* Pregnancy/Lactation: Female participants trying to conceive, pregnant, or lactating.
* Positive Pregnancy Test: Positive serum pregnancy test at screening or positive urine test at baseline.
* Other Trials: Concurrent participation in any other interventional clinical trial.
* Allergies: Known allergies to any components of the study vaccine.
* Anaphylaxis: History of anaphylaxis requiring medical intervention (including severe reactions to other mRNA vaccines).
* Cardiac History: History of stroke, transient ischemic attack, unstable angina, or myocardial infarction within 3 months prior to first dose.
* Myocarditis/Pericarditis: History of myocarditis or pericarditis.
* Heart Failure: Symptomatic congestive heart failure (NYHA Class III or IV), significant arrhythmia, or LVEF \<45%.
* QT Risk: History of risk factors for torsade de pointes or use of QT-prolonging medications.
* Vaccines: Received mRNA or live virus vaccine within 28 days of planned vaccination #1 (flu and COVID boosters prohibited in that window).
* Prior Malignancy: Prior malignancy except adequately treated basal/squamous cell skin cancer, in situ cervical cancer, or disease-free for ≥3 years.
* Organ Transplant: History of organ transplant requiring immunosuppression; unstable HIV/AIDS.
* Hepatitis: Known active hepatitis B or C.
* Compliance: Unable or unwilling to comply with study schedule/procedures.
* Injection/Blood Draw: Contraindication to IM injections or blood draws.

Conditions3

Interventions2

Locations2 sites

Related trials

• A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors — The Fourth Affiliated Hospital of Zhejiang University School of Medicine
• A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC — CuraCell TX AB
• A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia — Imperial College London
• A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Aptabio Therapeutics, Inc.
• A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) — Taipei Veterans General Hospital, Taiwan
• A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma. — Universitair Ziekenhuis Brussel
• A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma — NuCana plc
• A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) — Latin American Cooperative Oncology Group

Browse More Trials